TABLE OF CONTENTS | |||||||||||||||||||||||||||||||||||||
July 2017 Volume 16 Number 7 | Advertisement | ||||||||||||||||||||||||||||||||||||
In this issue Comment News and Analysis Research Highlights Reviews
|
| ||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Comment: Implications of cancer evolution for drug development Samra Turajlic & Charles Swanton p441 | doi:10.1038/nrd.2017.78 Tumour evolution, which results in the existence of multiple distinct populations of cancer cells within the same tumour and the same patient, is increasingly appreciated to have a key role in drug resistance. In this article, we discuss the implications for drug development, including approaches to reduce the likelihood of the emergence of drug resistance. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
NEWS AND ANALYSIS | Top | ||||||||||||||||||||||||||||||||||||
Chinese biopharma starts feeding the global pipeline Asher Mullard p443 | doi:10.1038/nrd.2017.94 A handful of discovered-in-China candidates have entered the global clinic, including a few first-in-class contenders. | |||||||||||||||||||||||||||||||||||||
NEWS IN BRIEF Genetic biomarker trumps tissue type in landmark oncology approval Asher Mullard p447 | doi:10.1038/nrd.2017.128 | |||||||||||||||||||||||||||||||||||||
Finding fault with Bial's fatal FAAH inhibitor Asher Mullard p447 | doi:10.1038/nrd.2017.129 | |||||||||||||||||||||||||||||||||||||
Biotech R&D spending continues to rise Asher Mullard p447 | doi:10.1038/nrd.2017.130 | |||||||||||||||||||||||||||||||||||||
BIOBUSINESS BRIEFS Market watch: Landscape for medical countermeasure development Christopher Milne, Zachary Peter Smith & Ranjana Chakravarthy p448 | doi:10.1038/nrd.2017.80 | |||||||||||||||||||||||||||||||||||||
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q3 2017 Sonny Nghiem p449 | doi:10.1038/nrd.2017.117 | |||||||||||||||||||||||||||||||||||||
AN AUDIENCE WITH Yong-Jun Liu p450 | doi:10.1038/nrd.2017.127 Yong-Jun Liu, head of research at Sanofi, discusses his push to refocus the company on internal early-stage drug discovery. | |||||||||||||||||||||||||||||||||||||
FROM THE ANALYST'S COUCH The ovarian cancer drug market Jennifer Bamford & Rachel M. Webster p451 | doi:10.1038/nrd.2017.92 This article discusses the impact of the recent approvals of poly ADP ribose polymerase (PARP) inhibitors on the market for ovarian cancer drugs, as well as potential future treatments such as immunotherapies. | |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
REVIEWS | Top | ||||||||||||||||||||||||||||||||||||
Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance Seth W. Dickey, Gordon Y. C. Cheung & Michael Otto p457 | doi:10.1038/nrd.2017.23 Efforts to combat bacterial infections by targeting virulence factors are gaining traction, fuelled by the potential to circumvent the development of antibacterial resistance and recent landmark approvals of antivirulence drugs. Here, Otto and colleagues examine the antivirulence drugs in development, highlighting the most promising targets and strategies, as well as caveats to using this approach. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Targeting glutamate signalling in depression: progress and prospects James W. Murrough, Chadi G. Abdallah & Sanjay J. Mathew p472 | doi:10.1038/nrd.2017.16 Changes in glutamate signalling have been implicated in major depression, and ketamine, which was recently found to act as a rapid-acting antidepressant, affects glutamate signalling in several ways. Murrough and colleagues give an overview of the development of glutamate-signalling modulators for depression and examine studies on the mechanisms of these agents. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles Lorenzo Galluzzi, José Manuel Bravo-San Pedro, Beth Levine, Douglas R. Green & Guido Kroemer p487 | doi:10.1038/nrd.2017.22 Dysregulated autophagy is associated with a variety of conditions, including cancer, neurodegenerative diseases, cardiovascular disorders and infectious diseases. However, despite significant efforts, no specific modulators of autophagy have yet been moved into the clinic. Here, Galluzzi et al. discuss the therapeutic potential of autophagy modulators and consider the key challenges that have limited their development. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
|
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved. |
No comments:
Post a Comment